-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients

PUBT·04/22/2026 02:20:50
Listen to the news
Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients
  • Immutep flagged an abstract on its cancer immunotherapy candidate eftilagimod alfa for poster presentation at ASCO 2026, with results scheduled for May 30.
  • Poster data are set to show cumulative clinical and translational findings that the drug drives rapid, sustained immune-cell activation in metastatic cancer patients.
  • Immutep expects the analysis to link immune activation signals with better overall survival outcomes across multiple late-stage cancer studies, supporting the program’s clinical rationale.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.